Increased water intake and alkalinization of urine is advised to prevent oxalate precipitation in urinary tract. In addition, Vitamin B6 (pyridoxine) is used to treat<unk> 1 because alanine glyoxylate transaminase requires pyridoxine as cofactor. In approximately one third of patients with<unk> 1, pyridoxine treatment decreases oxalate excretion and prevent kidney stone formation. Conversely, a restriction in oxalate intake is of limited use as the main source of oxalate is endogenous in<unk> . Lumasiran, an RNA interference therapeutic drug, is indicated for the treatment of<unk>  type 1 <unk> 1) in adults and children of all ages and is available under the UK Early Access to Medicines Scheme (EAMS). Lumasiran was approved for medical use in the European Union and in the United States in November 2020. In addition, there are a few agents under investigation in clinical trials for<unk> : Nedosiran (RNA interference therapeutic) for<unk> 1,<unk> 2, and<unk> 3; Stiripentol (antiepileptic drug); Oxabact (lyophilized Oxalobacter formigenes; and Reloxaliase (oxalate-digesting enzyme) for<unk>  Treatment of renal failure in<unk>  Kidney failure is a serious complication requiring treatment in its own right. Dialysis can control kidney failure but tends to be inadequate to dispose of excess oxalate. Renal transplant is more effective and is the<unk>  treatment of severe<unk> . Ultimately though, liver transplantation (often in addition to renal transplant) is required to correct the underlying metabolic defect.
Primary hyperoxaluria
Hawkinsinuria
Cystinuria
Alkaptonuria
Alpha-aminoadipic and alpha-ketoadipic aciduria
Trimethylaminuria
Aspartylglucosaminuria
Homocystinuria